Psoriasis is a chronic inflammatory immune-cell mediated disease, mediated by cross talk between epidermal keratinocytes, dermal vascular cells, and immunocytes. Psoriatic plaques are well defined and ...

Patients with psoriasis who had comorbidities were associated with worse health-related quality of life and impaired treatment outcomes with conventional therapy, whereas biologic treatments ...

Psoriasis has always been a common disease. Historically, its causes were obscure and surrounded by stigma; it wasn't until recently that scientists categorized it as an autoimmune condition. Indeed, ...

Inverse psoriasis forms discolored patches on the body’s skin folds, such as the armpits, genitals, and under the breasts or buttocks. Because these skin folds are called flexures, it’s also is known ...

A whopping 125 million people worldwide are living with psoriasis, so you'd think there would be more comprehensive info out there about it. Unfortunately, nope. There's still plenty of ...

Psoriasis is a skin condition that can appear differently on darker skin and lighter skin tones. The hallmark symptom of psoriasis — scaly, red patches of skin — can look purple or grayish on darker ...

Although some people with plaque psoriasis can control their symptoms by using topical treatments that are applied to the skin, some people with moderate or severe plaque psoriasis do not get enough ...

Unlike psoriatic arthritis, psoriasis has never had a generally accepted classification system. Discussions of the types of psoriasis generally fall into the extent, the clinical appearance and the ...

Findings showed that 88.5% of patients achieved target lesion Physician Global Assessment success at week 12. Tapinarof cream was found to be an effective treatment for plaque psoriasis of the head ...

The girl had guttate psoriasis, which often follows an acute streptococcal infection. Among patients with acute guttate psoriasis, two thirds have a preceding upper respiratory infection and one half ...

A hero has arrived in Protagonist Therapeutics’ story, in the form of a Johnson & Johnson-partnered psoriasis med that has just cleared lesions in a mid-stage trial. JNJ-2113, previously known as ...